These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 31886757)
1. 18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. Castello A; Rossi S; Lopci E Curr Radiopharm; 2020; 13(3):228-237. PubMed ID: 31886757 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
3. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281 [TBL] [Abstract][Full Text] [Related]
4. The predictive value of Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034 [TBL] [Abstract][Full Text] [Related]
5. Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy. Grambozov B; Kalantari F; Beheshti M; Stana M; Karner J; Ruznic E; Zellinger B; Sedlmayer F; Rinnerthaler G; Zehentmayr F Radiother Oncol; 2023 Aug; 185():109728. PubMed ID: 37301259 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983 [TBL] [Abstract][Full Text] [Related]
7. Comparison of prognostic values of primary tumor and nodal Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. Lee JW; Na JO; Kang DY; Lee SY; Lee SM Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385 [TBL] [Abstract][Full Text] [Related]
9. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of the Volumetric Parameters of Dual-Time-Point Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426 [No Abstract] [Full Text] [Related]
11. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer. Hu WD; Wang HC; Wang YB; Cui LL; Chen XH Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535 [TBL] [Abstract][Full Text] [Related]
12. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy. Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011 [TBL] [Abstract][Full Text] [Related]
13. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280 [TBL] [Abstract][Full Text] [Related]
14. [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer. Mattonen SA; Davidzon GA; Bakr S; Echegaray S; Leung ANC; Vasanawala M; Horng G; Napel S; Nair VS Tomography; 2019 Mar; 5(1):145-153. PubMed ID: 30854452 [TBL] [Abstract][Full Text] [Related]
15. Is there any improvement in clinical staging with Gedik GK; Yilmaz F Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(6):348-354. PubMed ID: 31378538 [TBL] [Abstract][Full Text] [Related]
16. Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer. Kong FS; Li L; Wang W; Campbell J; Waller JL; Piert M; Gross M; Cheng M; Owen D; Stenmark M; Huang KC; Frey KA; Ten Haken RK; Lawrence TS Radiother Oncol; 2019 Mar; 132():241-249. PubMed ID: 30389239 [TBL] [Abstract][Full Text] [Related]
17. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344 [TBL] [Abstract][Full Text] [Related]
18. Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy. Kim N; Kim JS; Geol Lee C PLoS One; 2020; 15(7):e0236350. PubMed ID: 32687531 [TBL] [Abstract][Full Text] [Related]
19. Role of Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725 [TBL] [Abstract][Full Text] [Related]
20. Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study. Kaumanns A; König D; Hojski A; Cattaneo M; Chirindel A; Wiese M; Tamm M; Lardinois D; Rothschild SI Lung Cancer; 2022 Nov; 173():14-20. PubMed ID: 36108578 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]